Assessment of the features of serum apolipoprotein profiles in chronic HCV infection: difference between HCV genotypes 1b and 2.

Abstract:

BACKGROUND:The life cycle of hepatitis C virus (HCV) is tightly associated with host lipoprotein metabolic pathways. Apolipoprotein is present on the outer surface of lipoprotein particles and plays an important role in lipoprotein metabolism. We aimed to elucidate the influence of chronic HCV infection on serum apolipoprotein profiles. METHODS:Fasting serum apolipoprotein profiles of 310 subjects with active or cleared HCV infection were examined. Subsequently, the association between chronic HCV infection and serum apolipoprotein levels was determined using multiple regression analysis. RESULTS:Active HCV infection was associated with high serum levels of apo A-II and low serum levels of apo C-II and C-III. HCV infection with both genotype 1b (G1b) and genotype 2 (G2) was associated with low serum levels of either apo C-II and C-III, whereas only HCV G1b infections caused elevated levels of apo A II and E. Among active HCV infections, HCV G1b was associated with an elevation in the serum apo E levels. Furthermore, IL28B non-major genotype (rs8099917 TG/GG) was associated with low levels of serum apo B and high levels of apoA-II, and advanced fibrosis was associated with low levels of apo B and C-II in G1b infection. CONCLUSIONS:Active HCV infection is distinctively associated with characteristic serum apolipoprotein profiles. The influence on apolipoprotein profiles varies with different HCV genotypes. Moreover, the genotype of IL28B and hepatic fibrosis affected serum apolipoproteins in G1b infection. Abnormalities in serum apolipoproteins may provide a clue to the elucidation of complex interactions between active HCV infection and lipid metabolism.

journal_name

Hepatol Int

journal_title

Hepatology international

authors

Seki N,Sugita T,Aida Y,Itagaki M,Ishiguro H,Sutoh S,Abe H,Tsubota A,Matsushima M,Aizawa Y

doi

10.1007/s12072-014-9572-2

subject

Has Abstract

pub_date

2014-10-01 00:00:00

pages

550-9

issue

4

eissn

1936-0533

issn

1936-0541

pii

10.1007/s12072-014-9572-2

journal_volume

8

pub_type

杂志文章
  • Management of primary sclerosing cholangitis and its complications: an algorithmic approach.

    abstract::Primary sclerosing cholangitis (PSC) is a rare cholestatic liver disease, characterized by multiple strictures and dilatations of the intra- and extrahepatic bile ducts, leading to progressive liver fibrosis, in 10-15% cholangiocarcinoma, and ultimately end-stage liver disease. The pathogenesis is poorly understood, b...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-020-10118-x

    authors: Prokopič M,Beuers U

    更新日期:2020-12-30 00:00:00

  • Hepatitis C virus (genotype 4)-associated mixed cryoglobulinemia vasculitis: effects of antiviral treatment.

    abstract:OBJECTIVE:Type II mixed cryoglobulinemia (MC) is a systemic vasculitis usually associated with hepatitis C virus (HCV). The present trial was performed to investigate the efficacy of therapy with pegylated interferon alfa-2a (PEG-IFN alfa-2a) plus ribavirin in patients with HCV-related MC vasculitis and evaluate the fa...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9303-x

    authors: El Khayat HR,Fouad YM,Ahmad EA,El Amin H,Ismael F,Rizk A

    更新日期:2012-06-01 00:00:00

  • Dynamic changes of T cell receptor repertoires in patients with hepatitis B virus-related acute-on-chronic liver failure.

    abstract:BACKGROUND AND AIMS:T cell-mediated immune injury plays a critical role in the pathogenesis of hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF). Given the high short-term mortality and crucial role of T cells in the disease progression, it is necessary to investigate the dynamics of T cell clones dur...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-019-10008-x

    authors: Shen G,Sun S,Huang J,Deng H,Xu Y,Wang Z,Tang X,Gong X

    更新日期:2020-01-01 00:00:00

  • Non-alcoholic hepatic steatosis attenuates hepatitis B virus replication in an HBV-immunocompetent mouse model.

    abstract:OBJECTIVE:The relationship between chronic hepatitis B virus (HBV) infection and fatty liver in patients remains unclear. Although high-fat diets-induced hepatic steatosis was proved to reduce HBV replication in transgenic mice, the interplay between HBV and fatty liver in immunocompetent mouse model is yet to be eluci...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-018-9877-7

    authors: Hu D,Wang H,Wang H,Wang Y,Wan X,Yan W,Luo X,Ning Q

    更新日期:2018-09-01 00:00:00

  • Combination and evolution of HBV mutant strains in the HBeAg-positive status predict clinical outcomes after HBeAg seroconversion.

    abstract:PURPOSE:We investigated whether the combined presence and evolution of hepatitis B virus (HBV) mutant strains in the hepatitis B e antigen (HBeAg)-positive status can predict clinical outcomes after HBeAg seroconversion. METHODS:One hundred and eighty-six patients with spontaneous HBeAg seroconversion were enrolled in...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9381-4

    authors: Chen CH,Lee CM,Wang JH,Hu TH,Hung CH,Changchien CS,Lu SN

    更新日期:2013-06-01 00:00:00

  • A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.

    abstract::Hepatitis C virus (HCV) treatment in HIV/HCV co-infected individuals has renewed relevance given the ongoing opioid crisis and rise of new HIV and HCV infections associated with injection drug use. Patients co-infected with HIV and HCV demonstrate increased rates of hepatic fibrosis, progression to liver failure, and ...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-018-9896-4

    authors: Abutaleb A,Sherman KE

    更新日期:2018-11-01 00:00:00

  • Live donor liver transplantation for alcoholic hepatitis.

    abstract::Liver transplantation is a definitive therapy for patients with end-stage liver disease and cirrhosis, with improvement in survival and quality of life. Patients are carefully screened and selected for this modality of treatment to achieve maximum survival benefit. For example, a patient with hepatocellular carcinoma ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-016-9770-1

    authors: Singal AK,Kamath PS

    更新日期:2017-01-01 00:00:00

  • Reversal of NASH fibrosis with pharmacotherapy.

    abstract::NAFLD is a spectrum of liver disease starting with fatty liver at one end of the spectrum and cirrhosis or liver cancer at the other end. Worldwide, NAFLD has become one of the most common liver diseases and it has also become one of the leading indications for liver transplantation. Our understanding of the NAFLD epi...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-019-09970-3

    authors: Alukal JJ,Thuluvath PJ

    更新日期:2019-09-01 00:00:00

  • Hepatitis B reactivation after chemotherapy: two decades of clinical research.

    abstract::Hepatitis due to hepatitis B virus reactivation after cytotoxic or immunosuppressive therapy is a serious cause of liver-related morbidity and mortality. With the characterization of the underlying pathogenesis, much progress in the management of this important clinical problem has been made in the past 2 decades. By ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9056-3

    authors: Lau GK

    更新日期:2008-06-01 00:00:00

  • Existence of cancer stem cells in hepatocellular carcinoma: myth or reality?

    abstract::The cancer stem cell (CSC) hypothesis has been disproved in many cancers. CSCs may exist in blood cancer, while many epithelial cancers may not have CSCs but tumor-initiating cells (TICs). Several independent studies have provided strong evidence for existence of CSCs in brain, skin, and colon cancers (Mani et al. in ...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-016-9777-7

    authors: Machida K

    更新日期:2017-03-01 00:00:00

  • Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.

    abstract::Worldwide, some 240 million people have chronic hepatitis B virus (HBV), with the highest rates of infection in Africa and Asia. Our understanding of the natural history of HBV infection and the potential for therapy of the resultant disease is continuously improving. New data have become available since the previous ...

    journal_title:Hepatology international

    pub_type: 杂志文章,实务指引

    doi:10.1007/s12072-015-9675-4

    authors: Sarin SK,Kumar M,Lau GK,Abbas Z,Chan HL,Chen CJ,Chen DS,Chen HL,Chen PJ,Chien RN,Dokmeci AK,Gane E,Hou JL,Jafri W,Jia J,Kim JH,Lai CL,Lee HC,Lim SG,Liu CJ,Locarnini S,Al Mahtab M,Mohamed R,Omata M,Park J,

    更新日期:2016-01-01 00:00:00

  • Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay.

    abstract:BACKGROUND:Possible serologic activity after hepatitis B surface antigen (HBsAg) seroclearance documented by conventional assays in chronic hepatitis B (CHB) has not been thoroughly investigated. METHODS:We determined the levels of serum hepatitis B virus (HBV) DNA, hepatitis B core-related antigen (HBcrAg), and linea...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9354-7

    authors: Seto WK,Tanaka Y,Wong DK,Lai CL,Shinkai N,Yuen JC,Tong T,Fung J,Hung IF,Yuen MF

    更新日期:2012-03-13 00:00:00

  • Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.

    abstract:BACKGROUND AND AIMS:Coronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 ...

    journal_title:Hepatology international

    pub_type: 杂志文章,meta分析

    doi:10.1007/s12072-020-10074-6

    authors: Wu Y,Li H,Guo X,Yoshida EM,Mendez-Sanchez N,Levi Sandri GB,Teschke R,Romeiro FG,Shukla A,Qi X

    更新日期:2020-09-01 00:00:00

  • Strategies to treat interferon-induced graft dysfunction after living donor liver transplantation for hepatitis C.

    abstract:PURPOSE:Interferon-induced graft dysfunction (IGD) is a poorly defined, unrecognized, but potentially serious condition for patients receiving antiviral drugs after liver transplantation for hepatitis C. METHODS:We evaluated the characteristics of 80 patients who received pegylated interferon-based antiviral treatment...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9496-2

    authors: Ikegami T,Wang H,Yoshizumi T,Toshima T,Aishima S,Fukuhara T,Furusyo N,Kotoh K,Shimoda S,Shirabe K,Maehara Y

    更新日期:2014-04-01 00:00:00

  • Epigenetic histone modifications in a clinically relevant rat model of chronic ethanol-binge-mediated liver injury.

    abstract:PURPOSE:Ethanol binge augments liver injury after chronic ethanol consumption in humans, but the mechanism behind the enhanced liver injury by ethanol binge is not known. In this study we used a clinically relevant rat model in which liver injury is amplified by binge after chronic ethanol treatment and investigated th...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-014-9546-4

    authors: Aroor AR,Restrepo RJ,Kharbanda KK,Shukla SD

    更新日期:2014-09-01 00:00:00

  • Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients.

    abstract:BACKGROUND AND OBJECTIVE:Cytokines have been reported to be involved in the cirrhosis and hepatic encephalopathy (HE). Many aspects on the correlation between minimal HE (MHE) and cytokine levels were still unclear. METHODS:Two hundred eighty-nine HBV-infected cirrhotic patients were grouped: non MHE (n = 156), MHE (n...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-015-9610-8

    authors: Li W,Li N,Wang R,Li Q,Wu H

    更新日期:2015-04-01 00:00:00

  • CSH guidelines for the diagnosis and treatment of drug-induced liver injury.

    abstract::Drug-induced liver injury (DILI) is an important clinical problem, which has received more attention in recent decades. It can be induced by small chemical molecules, biological agents, traditional Chinese medicines (TCM), natural medicines (NM), health products (HP), and dietary supplements (DS). Idiosyncratic DILI i...

    journal_title:Hepatology international

    pub_type: 社论

    doi:10.1007/s12072-017-9793-2

    authors: Yu YC,Mao YM,Chen CW,Chen JJ,Chen J,Cong WM,Ding Y,Duan ZP,Fu QC,Guo XY,Hu P,Hu XQ,Jia JD,Lai RT,Li DL,Liu YX,Lu LG,Ma SW,Ma X,Nan YM,Ren H,Shen T,Wang H,Wang JY,Wang TL,Wang XJ,Wei L,Xie Q,Xie W,

    更新日期:2017-05-01 00:00:00

  • Actinomycotic hepatic abscess.

    abstract::Actinomycotic hepatic abscess was diagnosed in a 46-year-old male driver from Ukraine presenting with the symptoms of malaise, loss of appetite, upper right quadrant pain, weight loss, and night sweats which had been present for last 2 months. Computed tomography (CT) of the abdomen revealed a hypodense mass in the le...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-007-9032-3

    authors: Tiftikci A,Vardareli EN,Kaban K,Peker O,Akansel S,Tozun N

    更新日期:2008-03-01 00:00:00

  • New drugs for NAFLD: lessons from basic models to the clinic.

    abstract::The term nonalcoholic fatty liver disease (NAFLD) comprises a spectrum of increasingly harmful conditions ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to liver fibrosis and end-stage cirrhosis. NAFLD is the currently most common form of chronic liver disease in both adults and ch...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-019-10001-4

    authors: Reimer KC,Wree A,Roderburg C,Tacke F

    更新日期:2020-01-01 00:00:00

  • The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH).

    abstract:BACKGROUND AND AIMS:The peroxisome proliferator-activated receptor-γ (PPAR-γ) ligand, piglitazone, enhances the degradation of branched-chain amino acids (BCAAs) in adipose tissue. However, it remains unknown whether pioglitazone influences the plasma amino acids (AA) profile in patients with nonalcoholic steatohepatit...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-012-9395-y

    authors: Kakazu E,Kondo Y,Ninomiya M,Kimura O,Nagasaki F,Ueno Y,Shimosegawa T

    更新日期:2013-06-01 00:00:00

  • Immunological cure of HBV infection.

    abstract::Chronic hepatitis B virus (HBV) infection is a major global health burden and cure is rarely achieved by current antiviral therapies. Therefore, there is an urgent need for new therapeutic options. Immune modulation with the goal to restore dysfunctional HBV-specific immunity is an interesting target for new therapeut...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-018-9912-8

    authors: Lang J,Neumann-Haefelin C,Thimme R

    更新日期:2019-03-01 00:00:00

  • Procaine inhibits the proliferation and DNA methylation in human hepatoma cells.

    abstract:PURPOSE:Transcriptional silencing of tumor suppressor genes associated with DNA hypermethylation has been known as a hallmark of human cancer. In this study, we revealed that a local anesthetic, procaine (PCA), possessed growth-inhibitory and demethylating effect on human hepatoma cells in vitro and in vivo. METHODS:T...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-007-9014-5

    authors: Tada M,Imazeki F,Fukai K,Sakamoto A,Arai M,Mikata R,Tokuhisa T,Yokosuka O

    更新日期:2007-09-01 00:00:00

  • New therapeutic targets in alcoholic hepatitis.

    abstract::Alcoholic liver disease (ALD) is a leading cause of liver-related morbidity and mortality worldwide. ALD encompasses a spectrum of disorders including asymptomatic steatosis, steatohepatitis, fibrosis, cirrhosis and its related complications, and the acute-on-chronic state of alcoholic hepatitis. While multidisciplina...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-015-9701-6

    authors: Arsene D,Farooq O,Bataller R

    更新日期:2016-07-01 00:00:00

  • Association of the Laennec staging system with degree of cirrhosis, clinical stage and liver function.

    abstract:OBJECTIVES:The aim of this study was to investigate the association of the Laennec staging system with degree of cirrhosis, clinical stage and liver function. METHODS:Liver biopsy was performed for 30 patients with hepatitis B cirrhosis to test the content of hydroxyproline in hepatic tissue, judge the degree of cirrh...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-015-9648-7

    authors: Wang W,Li J,Pan R,A S,Liao C

    更新日期:2015-10-01 00:00:00

  • An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma.

    abstract:AIM:Tamibarotene is a synthetic retinoid expected to inhibit tumor-cell proliferation and to induce apoptosis by selective interaction with retinoic acid receptor α/β. We conducted an open-label phase I/II study to determine the maximum tolerated dose (MTD) and recommended dose (RD), and to evaluate the pharmacokinetic...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-013-9459-7

    authors: Kanai F,Obi S,Fujiyama S,Shiina S,Tamai H,Mochizuki H,Koike Y,Imamura J,Yamaguchi T,Saida I,Yokosuka O,Omata M

    更新日期:2014-01-01 00:00:00

  • A low steady HBsAg seroprevalence is associated with a low incidence of HBV-related liver cirrhosis and hepatocellular carcinoma in Mexico: a systematic review.

    abstract::To address the relationship between hepatitis B virus (HBV) endemicity and HBV-related liver diseases in Mexico. Research literature reporting on HBsAg and antibody to hepatitis B core antigen (anti-HBc) prevalence in Mexican study groups were searched in NLM Gateway, PubMed, IMBIOMED, and others. Weighted mean preval...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-008-9115-9

    authors: Roman S,Panduro A,Aguilar-Gutierrez Y,Maldonado M,Vazquez-Vandyck M,Martinez-Lopez E,Ruiz-Madrigal B,Hernandez-Nazara Z

    更新日期:2009-06-01 00:00:00

  • Biology of portal hypertension.

    abstract::Portal hypertension develops as a result of increased intrahepatic vascular resistance often caused by chronic liver disease that leads to structural distortion by fibrosis, microvascular thrombosis, dysfunction of liver sinusoidal endothelial cells (LSECs), and hepatic stellate cell (HSC) activation. While the basic ...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-017-9826-x

    authors: McConnell M,Iwakiri Y

    更新日期:2018-02-01 00:00:00

  • Depression, fatigue and neurocognitive deficits in chronic hepatitis C.

    abstract::Patients with chronic hepatitis C virus (HCV) infection experience a range of symptoms including depression, fatigue and neurocognitive deficits, impairing quality of life. Depression, in particular, may be reactive to increased psychosocial stress, and the physical symptoms of advanced HCV or associated comorbidities...

    journal_title:Hepatology international

    pub_type: 杂志文章,评审

    doi:10.1007/s12072-018-9879-5

    authors: Yeoh SW,Holmes ACN,Saling MM,Everall IP,Nicoll AJ

    更新日期:2018-07-01 00:00:00

  • De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naïve HBeAg-negative chronic hepatitis B patients.

    abstract:PURPOSE:Either combination treatment or monotherapy using agents with a high genetic barrier are recommended for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB). The aim of this study was to compare effect of naïve HBeAg-negative CHB patients with either de novo combination of lamivudine (LAM) and adef...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-010-9243-x

    authors: Wang LC,Chen EQ,Cao J,Liu L,Zheng L,Li DJ,Xu L,Lei XZ,Liu C,Tang H

    更新日期:2011-06-01 00:00:00

  • Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management.

    abstract::Chronic hepatitis B virus (HBV) infection is endemic in the Asian-Pacific region, and reactivation of HBV post-cancer chemotherapy has become an emerging clinical challenge. Patients with detectable serum HBV DNA before chemotherapy and those receiving intensive chemotherapy are particularly at a risk of HBV reactivat...

    journal_title:Hepatology international

    pub_type: 杂志文章

    doi:10.1007/s12072-011-9279-6

    authors: Liu CJ,Chen PJ,Chen DS,Kao JH

    更新日期:2013-06-01 00:00:00